Evidence map›Paper›PMID 34992217›Full record

ArticleOncogene2022

Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.

Tongtong Kan, Shupeng Zhang, Shengtao Zhou, Ya Zhang, Yun Zhao, Yinghua Gao, Tao Zhang, Feng Gao, Xin Wang, Linjie Zhao and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Cancer-associated fibroblast-derived SEMA3C facilitates colorectal cancer liver metastasis via NRP2-mediated MAPK activation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  16. Review
  17. INHBABMC cancer · 2025
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tongtong KanDepartment of Biomedical Sciences, City University of Hong Kong, Hong Kong, China. tongtongkan@hotmail.com.ORCID http://orcid.org/0000-0001-9131-9129
Shupeng ZhangDepartment of Pathology, The Second Affiliated Hospital of Shandong First Medical University, Taian, China.
Shengtao ZhouDepartment of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second Hospital and State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China Hospital, Sichuan University, Chengdu, China.ORCID http://orcid.org/0000-0001-8322-5536
Ya ZhangDepartment of Pathology, The Second Affiliated Hospital of Shandong First Medical University, Taian, China.
Yun ZhaoDepartment of Pathology, Taian Tumor Prevention and Treatment Hospital, Taian, China.
Yinghua GaoDepartment of Pathology, The Second Affiliated Hospital of Shandong First Medical University, Taian, China.
Tao ZhangDepartment of Biostatistics, School of Public Health, Shandong University, Jinan, China.
Feng GaoDepartment of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.
Xin WangDepartment of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0000-0002-5122-2418
Linjie ZhaoDepartment of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second Hospital and State Key Laboratory of Biotherapy/Collaborative Innovation Center, West China Hospital, Sichuan University, Chengdu, China.
Mengsu YangDepartment of Biomedical Sciences, City University of Hong Kong, Hong Kong, China. bhmyang@cityu.edu.hk.ORCID http://orcid.org/0000-0003-2083-2296

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancers (EOCs) are sensitive to chemotherapy but will ultimately relapse and develop drug resistance. The origin of EOC recurrence has been elusive due to intra-tumor heterogeneity. Here we performed single-cell RNA sequencing (scRNA-seq) in 13,369 cells from primary, untreated peritoneal metastasis, and relapse tumors. We used time-resolved analysis to chart the developmental sequence of cells from the metastatic tumors, then traced the earliest replanting cells back to the primary tumors. We discovered seven distinct subpopulations in primary tumors where the CYR61

Indexed as

Carcinoma, Ovarian EpithelialCysteine-Rich Protein 61Neoplasm Recurrence, LocalOvarian NeoplasmsCancer-Associated FibroblastsFemaleGene Expression Regulation, NeoplasticHumansRNA-SeqSingle-Cell AnalysisSingle-Cell Gene Expression AnalysisCCN1 protein, humanCysteine-Rich Protein 61

Identifiers

PMID34992217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.